Now Playing
News|Videos|December 15, 2023
Evolving Paradigms in the Detection and Treatment of Prostate Cancer
Author(s)Rana R. McKay, MD, Tanya B. Dorff, MD
Expert oncologists offer insights into conquering resistance, reimagining screening, and realizing the paradigm-shifting potential of advances in biomarker-driven precision medicine.
Advertisement
Advertisement
Related to this article
CHMP offerred a positive opinion supporting extension of melflufen to third-line, lenalidomide-refractory multiple myeloma.
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
Mayo Clinic researchers reported data for minibeam radiotherapy for treatment-resistant cancers in or near the skin.
Mosunetuzumab plus lenalidomide met the CELESTIMO trial's primary end point, improving PFS in relapsed/refractory follicular lymphoma.
The latest updates to the NCCN Guidelines for multiple myeloma expand minimal residual disease testing guidance.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
A marketing authorization application for lirafugratinib in previously treated FGFR2-altered metastatic cholangiocarcinoma has been submitted to the EMA.
Toon Van Gorp, MD, PhD, discusses NAPISTAR 1-01 trial design, safety findings, and efficacy across dose levels of TUB-040 in ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears sNDA for Taletrectinib With Updated DOR Data in ROS1+ NSCLC
2
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma
3
CHMP Recommends Label Expansion of Melflufen to Third-Line Lenalidomide-Refractory Multiple Myeloma
4
Mosunetuzumab Plus Lenalidomide Improves PFS in R/R Follicular Lymphoma
5